🇺🇸 FDA
Patent

US 11491145

Combination therapies comprising targeted therapeutics

granted A61KA61K31/4375A61K31/502

Quick answer

US patent 11491145 (Combination therapies comprising targeted therapeutics) held by Madrigal Pharmaceuticals, Inc. expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Madrigal Pharmaceuticals, Inc.
Grant date
Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/4375, A61K31/502, A61K31/5025, A61K45/06